{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:32:22Z","timestamp":1777883542336,"version":"3.51.4"},"reference-count":69,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Addiction Journal"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Healthcare providers may be utilizing central nervous system (CNS) depressants to reduce opioid use due to recent changes in public policy. Combination use of these agents with opioids increases the risk of respiratory depression and death. Healthcare expenditures by individuals using these drug combinations have not been previously quantified. We sought to characterize healthcare costs and expenditures associated with a population reporting concurrent CNS depressants and opioid use compared with nonopioid analgesics in the United States from 2009 to 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A serial cross-sectional design was used to compare the healthcare expenditures of adult Medical Expenditure Panel Survey respondents who were prescribed nonopioid analgesics, opioids only, opioids\/benzodiazepines (BZD), opioids\/BZD\/skeletal muscle relaxants (SMR), or opioids\/gabapentin (gaba) using pooled data from 2009 to 2019. Expenditure (cost and resource utilization) categories included inpatient, outpatient, office-based, and prescription medicine. Average marginal effects were used to compare survey-weighted annual costs and resource utilizations across the groups as compared to nonopioid analgesic respondents, adjusted for covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A weighted total of 34\u2009241\u2009838 individuals were identified. Most were opioid-only respondents (46.5%), followed by nonopioid analgesic (43.4%), opioid\/BZD (5.3%), opioid-gaba (3.5%), and opioid\/BZD\/SMR respondents (1.3%). In comparison to the study groups with nonopioid analgesics, opioid-gaba users had the highest significant incremental cost difference among the different pairings (+$11\u2009684,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u2009.001). Opioid-gaba, opioid\/BZD, and opioid\/BZD\/SMR respondents had significantly higher inpatient, emergency department, and prescription drug costs and use compared to nonopioid analgesic respondents. Opioid-only respondents had higher outpatient and office-based costs and visits compared to nonopioid analgesic respondents.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>As healthcare providers seek to utilize fewer opioids for pain management, attention must be paid to ensuring safe and effective use of concurrent CNS depressants to mitigate high healthcare costs and burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/29767342241247372","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T08:36:51Z","timestamp":1715157411000},"page":"631-644","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of Opioid and Concurrent Benzodiazepine, Skeletal Muscle Relaxant, and Gabapentinoid Usage on Healthcare Expenditure and Resource Utilization: A Serial Cross-Sectional Study, 2009 to 2019"],"prefix":"10.1177","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-7824","authenticated-orcid":false,"given":"Aryana","family":"Sepassi","sequence":"first","affiliation":[{"name":"University of California, Irvine School of Pharmacy &amp; Pharmaceutical Sciences, Irvine, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangho","family":"Suh","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britney","family":"Stottlemyer","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bounthavong","sequence":"additional","affiliation":[{"name":"University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA"},{"name":"U.S. Department of Veteran Affairs, Veterans Health Administration, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.07.025"},{"key":"e_1_3_2_3_2","unstructured":"Joint Economic Committee Democrats. 2022. The economic toll of the opioid crisis reached nearly $1.5 trillion in 2020. Accessed April 7 2023. https:\/\/www.jec.senate.gov\/public\/_cache\/files\/67bced7f-4232-40ea-9263-f033d280c567\/jec-cost-of-opioids-issue-brief.pdf"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.18543"},{"key":"e_1_3_2_5_2","unstructured":"CDC Injury Center. Death rate maps and graphs. Drug overdose deaths. 2022. Accessed April 7 2023. https:\/\/www.cdc.gov\/drugoverdose\/deaths\/index.html"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-021-00415-5"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1243"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnac068"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12655"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01432-7"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0919"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1807"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000828"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038692"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2011.554778"},{"key":"e_1_3_2_16_2","first-page":"1419","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2013-2017","volume":"67","author":"Scholl L","year":"2019","unstructured":"Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths\u2014United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2019;67:1419-1427.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-020-01012-5"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Dowell D Haegerich TM Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain\u2014United States 2016. Morbidity and Mortality Weekly Report (MMWR). Accessed April 7 2023. https:\/\/www.cdc.gov\/mmwr\/volumes\/65\/rr\/rr6501e1.htm","DOI":"10.15585\/mmwr.rr6501e1"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"e_1_3_2_20_2","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. 2019. Accessed April 7 2023. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00228"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6045017"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31793-8"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550490601186238"},{"key":"e_1_3_2_25_2","unstructured":"Agency for Healthcare Research and Quality. MEPS HC-216 2019 Full Year Consolidated Data File Documentation. 2021. Accessed December 1 2022. https:\/\/meps.ahrq.gov\/data_stats\/download_data\/pufs\/h216\/h216doc.shtml"},{"key":"e_1_3_2_26_2","unstructured":"Chowdhury SR Machin SR Gwet KL. Sample designs of the Medical Expenditure Panel Survey Household Component 1996-2006 and 2007-2016. Methodology Report #33. 2019. Accessed December 1 2022. https:\/\/meps.ahrq.gov\/data_files\/publications\/mr33\/mr33.shtml"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_2_28_2","unstructured":"Agency for Healthcare Research and Quality. MEPS HC-213A Prescribed Medicines Documentation. 2021. Accessed April 7 2023. https:\/\/meps.ahrq.gov\/data_stats\/download_data\/pufs\/h213a\/h213adoc.shtml"},{"key":"e_1_3_2_29_2","unstructured":"Agency for Healthcare Research and Quality. MEPS HC-214 2019 Medical Conditions Documentation. 2021. Accessed April 7 2023. https:\/\/meps.ahrq.gov\/data_stats\/download_data\/pufs\/h214\/h214doc.shtml"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2019.12.018"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2012.694598"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622"},{"key":"e_1_3_2_33_2","unstructured":"Agency for Healthcare Research and Quality. 2023. Using appropriate price indices for analyses of health care expenditures or income across multiple years. Accessed April 7 2023. https:\/\/meps.ahrq.gov\/about_meps\/Price_Index.shtml#t1a1"},{"issue":"4","key":"e_1_3_2_34_2","first-page":"188","article-title":"Charlson Comorbidity Index: ICD-9 update and ICD-10 translation","volume":"12","author":"Glasheen WP","year":"2019","unstructured":"Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12(4):188-197.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_2_35_2","unstructured":"Agency for Healthcare Research and Quality. MEPS-HC Summary Data Tables Technical Notes. 2013. Accessed April 7 2023. https:\/\/meps.ahrq.gov\/survey_comp\/hc_technical_notes.shtml"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v009.i08"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500102"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/701235"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7063"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200904"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7664"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201900446"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j760"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.7856"},{"key":"e_1_3_2_45_2","unstructured":"IMS Institute for Healthcare Informatics. Medicines use and spending shifts: a review of the use of medicines in the US in 2014. 2015. Accessed April 7 2023. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/medicines-use-and-spending-shifts-in-the-us-in-2014.pdf"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.3.246"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(02)00255-5"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1704633"},{"key":"e_1_3_2_49_2","unstructured":"Kouzoukas D Lazio JW. Advance Notice of Methodological Changes for Calendar Year (CY) 2019 for Medicare Advantage (MA) Capitation Rates Part C and Part D Payment Policies and 2019 draft Call Letter. 2018. Centers for Medicare and Medicaid Services. Accessed April 7 2023. https:\/\/www.cms.gov\/medicare\/health-plans\/medicareadvtgspecratestats\/downloads\/advance2019part2.pdf"},{"issue":"6","key":"e_1_3_2_50_2","first-page":"447","article-title":"Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans","volume":"16","author":"Margolis JM","year":"2010","unstructured":"Margolis JM, Cao Z, Onukwugha E, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. Am J Manag Care. 2010;16(6):447-456.","journal-title":"Am J Manag Care"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1390081"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3182a9a896"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12689"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000591"},{"key":"e_1_3_2_55_2","unstructured":"IQVIA Institute. Prescription opioid trends in the United States. 2020. Accessed April 7 2023. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/prescription-opioid-trends-in-the-united-states"},{"key":"e_1_3_2_56_2","unstructured":"CDC Injury Center. Drug overdose. United States opioid dispensing rate maps. 2022. Accessed April 7 2023. https:\/\/www.cdc.gov\/drugoverdose\/rxrate-maps\/index.html"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2009.12.011"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2015.1673"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.17226\/24781"},{"key":"e_1_3_2_60_2","unstructured":"PDMP Center of Excellence. Briefing on PDMP Effectiveness. 2013. Accessed April 7 2023. https:\/\/www.ojp.gov\/pdffiles1\/bja\/247133.pdf"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.09.022"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.4137\/SART.S2345"},{"key":"e_1_3_2_63_2","unstructured":"Urban Institute. Medicaid coverage of effective treatment for opioid use disorder. 2017. Accessed April 7 2023. https:\/\/www.urban.org\/research\/publication\/medicaid-coverage-effective-treatment-opioid-use-disorder"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000703"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0473"},{"key":"e_1_3_2_66_2","unstructured":"Rep. Bonamici S [D O 1]. H.R.34\u2014114th Congress (2015-2016): 21st Century Cures Act. 2016. Accessed April 7 2023. https:\/\/www.congress.gov\/bill\/114th-congress\/house-bill\/34"},{"key":"e_1_3_2_67_2","unstructured":"Rep. Connolly GE [D V 11]. Text\u2014H.R.2617\u2014117th Congress (2021-2022): Consolidated Appropriations Act 2023. 2022. Accessed April 7 2023. https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/2617"},{"key":"e_1_3_2_68_2","unstructured":"Rep. Walden G [R O 2]. H.R.6\u2014115th Congress (2017-2018): SUPPORT for Patients and Communities Act. 2018. Accessed April 7 2023. https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/6"},{"key":"e_1_3_2_69_2","unstructured":"Sen. Whitehouse S [D R]. Text\u2014S.524\u2014114th Congress (2015-2016): Comprehensive Addiction and Recovery Act of 2016. 2016. Accessed April 7 2023. https:\/\/www.njleg.state.nj.us\/bill-search\/2022\/S524"},{"key":"e_1_3_2_70_2","unstructured":"Substance Abuse and Mental Health Services Administration. Removal of DATA Waiver (X-Waiver) Requirement. 2023. Accessed April 7 2023. https:\/\/medi-calrx.dhcs.ca.gov\/cms\/medicalrx\/static-assets\/documents\/provider\/dur\/educational-articles\/dured_Removal_of_Data_Waiver_X-Waiver_Requirement.pdf"}],"container-title":["Substance Use &amp; Addiction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241247372","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/29767342241247372","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/29767342241247372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:49:42Z","timestamp":1777600182000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/29767342241247372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1177\/29767342241247372"],"URL":"https:\/\/doi.org\/10.1177\/29767342241247372","relation":{},"ISSN":["2976-7342","2976-7350"],"issn-type":[{"value":"2976-7342","type":"print"},{"value":"2976-7350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]}}}